The Province of Prince Edward Island and SEKISUI Diagnostics announce a Charlottetown expansion.

FOR IMMEDIATE RELEASE

JUNE 16, 2025 – BOSTON, Massachusetts

SEKISUI Diagnostics and the Government of Prince Edward Island today announced a $16 million (CAD) capital investment in the company’s Charlottetown facilities as part of an ambitious business expansion into contract manufacturing of reagents for global clients.

Premier Lantz announced that the province is contributing $3.9 million in capital investment for the initial facility build-out, repayable on a lease-back arrangement and a labour rebate in support of the Charlottetown expansion.

Sekisui Diagnostics anticipates that the new 22,000 square-foot facility in Charlottetown will be completed by 2026 and will go directly into production for a European customer. Output capacity will triple from 4,500L to 20,000L batch sizes. The expansion will add 25 highly skilled positions to the company’s local workforce of 200 employees.

The Hon. Rob Lantz, Premier of Prince Edward Island and Bob Schruender, President and CEO, SEKISUI Diagnostics shared the podium at the Canada Pavilion during the BIO International 2025 Conference and Exhibition to make the announcement.

“If your medical professional ordered a diagnostic test for you, chances are likely a SEKISUI Diagnostics product made that possible. One of Canada’s best kept secrets is that Prince Edward Island is a leader in our national bioscience ecosystem and has been improving the lives of patients both at home and around the globe for over 50 years,” said Premier Rob Lantz. “Investments, such as what we announced today, are a testament to our province’s enduring commitment to advancing the success of both health innovation and prosperity at home through our highly innovative cluster of bio companies.”

“We are proud that this investment will continue to strengthen our capabilities as we ramp up to break into the market of contract manufacturing on a much larger scale,” shared Bob Schruender, President and CEO SEKISUI Diagnostics. “We thank the Government of Prince Edward Island for their support of this expansion and ongoing belief in both our company and also in the growth of the bioscience sector over many years.”

“We applaud the strength of the private, public partnership that was reflected by today’s announcement,” stated Rory Francis, CEO, PEI BioAlliance. “As a sector we have worked closely with government, industry, and academic partners over the last 20 years to grow bio-based small and medium-sized enterprises, foster cutting-edge biotechnology, and ultimately enrich the lives of patients and our province.”

Quick Facts:

• SEKISUI Diagnostic’s product lines include clinical chemistry reagents, i.e. “tests for Cardiac, Liver and general health” point-of-care tests, blood collection tube materials as well as enzymes and specialty biochemicals.
• As an anchor Prince Edward Island biosciences company Sekisui Diagnostics has had a long-term partnership with the provincial government completing 7 building expansions and over $40 million in capital investment within the last 10 years.
• This project creates 25 new and highly skilled employment opportunities to the company’s PEI site, recruiting from the local workforce, along with roles specialized for University and College graduates.
• Construction of the 22,000 square foot facility is expected to be completed in 2026.
• The bioscience sector in Prince Edward Island grosses over $600 million in revenue annually.

About Sekisui Diagnostics

With over 40 years of experience, SEKISUI Diagnostics’ mission is to enhance life with science and improve the health of all people by supplying innovative medical diagnostics globally to physicians, hospitals, laboratories and alternate testing locations as well as partnerships with the world’s leading healthcare companies supporting accurate and timely patient diagnosis across the globe.

Media Contacts

Lisa Turner
SEKISUI Diagnostics
Director, Communications & Commercial Marketing
lisa.turner@sekisui-dx.com

Bobbi Jo Walker
PEI BioAlliance
Director, Communications and Marketing
bobbijo@peibioalliance.com